2016
Antipsychotic-Induced Weight Gain in First-Episode Psychosis Patients: A Meta-Analysis of Differential Effects of Antipsychotic Medications
Tek C, Kucukgoncu S, Guloksuz S, Woods SW, Srihari VH, Annamalai A. Antipsychotic-Induced Weight Gain in First-Episode Psychosis Patients: A Meta-Analysis of Differential Effects of Antipsychotic Medications. FOCUS The Journal Of Lifelong Learning In Psychiatry 2016, 14: 370-377. PMID: 31997958, PMCID: PMC6988756, DOI: 10.1176/appi.focus.140308.Peer-Reviewed Original Research
2015
Antipsychotic‐induced weight gain in first‐episode psychosis patients: a meta‐analysis of differential effects of antipsychotic medications
Tek C, Kucukgoncu S, Guloksuz S, Woods SW, Srihari VH, Annamalai A. Antipsychotic‐induced weight gain in first‐episode psychosis patients: a meta‐analysis of differential effects of antipsychotic medications. Early Intervention In Psychiatry 2015, 10: 193-202. PMID: 25962699, PMCID: PMC5589463, DOI: 10.1111/eip.12251.Peer-Reviewed Original ResearchConceptsFirst-episode psychosisAP medicationFEP patientsBody weight gainBMI increaseWeight gainAP useBody mass index (BMI) changeSignificant body weight gainWeight gain riskMore weight gainComprehensive literature searchMean weight gainMeta-regression analysisBaseline weightBMI changeModifiable factorsBMI differencesMedicationsBMI outcomesPlaceboHigher weight gainBMILiterature searchPatients
2013
Investigating the safety and efficacy of naltrexone for anti-psychotic induced weight gain in severe mental illness: study protocol of a double-blind, randomized, placebo-controlled trial
Tek C, Guloksuz S, Srihari VH, Reutenauer EL. Investigating the safety and efficacy of naltrexone for anti-psychotic induced weight gain in severe mental illness: study protocol of a double-blind, randomized, placebo-controlled trial. BMC Psychiatry 2013, 13: 176. PMID: 23805859, PMCID: PMC3702521, DOI: 10.1186/1471-244x-13-176.Peer-Reviewed Original ResearchConceptsSevere mental illnessEfficacy of naltrexoneWeight gainOutcome measurementsHealth problemsMental illnessGreater New Haven areaTumor necrosis factor alphaWeight lossCurrent available medicationsPlacebo-controlled trialHigh-sensitivity CRPOpioid receptor antagonistSecondary outcome measuresSerum lipid profilePrimary outcome measurementBody mass indexD2 receptor blockadeEffects of naltrexoneNovel pharmacological optionsNecrosis factor alphaDoses of naltrexoneMajor health problemRates of obesitySignificant weight loss
2011
Insomnia is frequent in schizophrenia and associated with night eating and obesity
Palmese LB, DeGeorge PC, Ratliff JC, Srihari VH, Wexler BE, Krystal AD, Tek C. Insomnia is frequent in schizophrenia and associated with night eating and obesity. Schizophrenia Research 2011, 133: 238-243. PMID: 21856129, PMCID: PMC5581545, DOI: 10.1016/j.schres.2011.07.030.Peer-Reviewed Original ResearchConceptsBody mass indexQuality of lifeSleep difficultiesMass indexClinical insomniaSevere insomniaNight eatingPoor sleepPsychiatric symptomsTypes of antipsychoticsPrevalence of insomniaRelationship of sleepProminent clinical concernBrief cognitive assessmentIndependent predictorsPoint prevalenceClinical variablesClinical careSleep patternsSchizoaffective disorderClinical concernInsomniaLow qualityWeight gainSchizophrenia